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RESUMO – A diversidade de apresentações clínicas da síndrome de reconstituição imune faz da mesma um desafio 
clínico, na medida em que é difícil o manejo de infecções oportunistas e outras condições clínicas relacionadas com 
tal síndrome. A relevância da mencionada síndrome o Sarcoma de Kaposi após o início da terapia antiretroviral é 
notável, principalmente em países que possuem altos níveis de transmissão de doenças sexualmente transmissíveis e 
HIV. Desta forma, clínicos e dermatologistas devem estar atentos para identificar sinais e sintomas dessa progressão 
neoplásica e diferenciá-los do Sarcoma de Kaposi relacionado à síndrome de reconstituição imune de acordo com 
os critérios de classificação recentes da doença. Vital mencionar que terapia anti-retroviral não deve ser interrompida 
na maioria dos casos. 
PALAVRAS-CHAVE – Infecção por VIH; Sarcoma de Kaposi; HAART.
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: 
A POTENTIAL PITFALL IN THE MANAGEMENT OF KAPOSI’S 
SARCOMA IN HIV POSITIVE PATIENTS? – A CASE REPORT
ABSTRACT – The variety of immune reconstitution inflammatory syndrome’s (IRIS) clinical presentations makes this syn-
drome a challenge, in that it is difficult to manage opportunistic infections and other serious clinical conditions related 
to the manifestation of this syndrome. The relevance of immune reconstitution inflammatory syndrome – associated with 
Kaposi sarcoma (IRIS-KS) after initiation of highly active antiretroviral therapy (HAART) is noteworthy, mainly in coun-
tries that still have high levels of transmission of sexually transmitted diseases and HIV. Clinicians and dermatologists 
should be aware to identify signs and symptoms of this neoplasm progression and to differentiate them from KS related 
IRIS according to the recent classification criteria of this disease and antiretroviral therapy should not be discontinued 
in the most cases.
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INTRODUCTION
Kaposi’s Sarcoma (KS) is the most frequent neo-
plasm in homosexual and bisexual men with AIDS1,2. 
An analysis of 107 patients with AIDS-KS in São Paulo 
– Brazil found it to occur mainly in men (94.4%); one 
fourth were identified as HIV seropositive after a diag-
nosis of KS3, illustrating the high incidence of HIV in our 
country and the correlation between AIDS and KS. 
Another virus is also linked to this neoplasm and 
plays an etiopathological role: the Human Herpes Virus 
8 (HHV-8) often referred to as KS associated herpes 
virus4. Evidences indicate that HAART containing at least 
one inhibitor of HIV protease or a non nucleoside rever-
se transcriptase inhibitor can reduce the incidence or in-
duce the regression of KS and of other AIDS-associated 
tumors5-7. This can be attributed to Three factors can 
be linked to that action: the reduction in HIV viral load, 
HIV Tat protein an inflammatory cytokine the improve-
ment in CD8+ cytotoxic response against HHV-8; and 
the anti-inflammatory and anti-angiogenic properties of 
some drugs included in HAART. All these three actions 
result in directly inhibiting HIV-KS8. 
However, in a few HIV seropositive patients, HAART-
-induced improvement in immune status (temporally 
related to an increase in the host’s CD4+ lymphocyte 
count) paradoxically results in recrudescent cutaneous 
and/or visceral KS, attributed to an inflammatory reac-
tion to an opportunistic pathogen or tumor antigen that 
occurs early after initiation of HAART, the so called im-
mune reconstitution inflammatory syndrome (IRIS)9. 
CASE REPORT
A 35-year-old, male, born in Rio de Janeiro - Brazil, 
sought medical treatment in July 2010 because of strong 
pain in the epigastric region and asthenia accompanied 
by loss of appetite. He had no previous history of sexually 
transmitted infections or drug use. During the investiga-
tion, the patient was diagnosed as HIV positive and in 
September 2010, small and numerous violaceous no-
dules appeared only on both legs. In early December 
2010, laboratory investigations showed an HIV viral 
load of 172,950 copies per millimeter and CD4+ count 
of 214 cells/mm3 and antiretroviral therapy (HAART) 
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Fig. 1 - Ulcerated Kaposi’s Sarcoma lesion with a clean base 
and well-defined violaceous borders on the right leg.
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was implemented. The patient was referred to the STDs 
section of Professor Rubem David Azulay Dermatology 
Institute, Santa Casa da Misericórdia Hospital, Rio de 
Janeiro, Brazil.
In January 2011, six weeks after the initiation of 
HAART (zidovudine, lamivudine, and efavirenz), the 
patient returned referring worsening of the lesions and 
fever. Physical examination revealed new violaceous 
and painful nodules and ulcerated lesions, with a clean 
base and well-defined borders on the right leg (Fig. 1), 
chest (Fig. 2) and upper limbs. Neither mucocutaneous 
KS nor symptoms of visceral involvement were present. 
VDRL and FTA-abs tests for syphilis were negative.
A biopsy was taken from a nodular lesion and histo-
logically diagnosed as KS (Figs. 3 and 4). By this time, 
the HIV viral load was 410 copies per millimeter and 
CD4+ count was 370 cells per mm3. 
Four weeks after the biopsy, the majority of ulcera-
ted and nodular violaceous lesions improved and the 
patient had no further complaints, even without thera-
peutic changes.  
DISCUSSION
Two important pieces of information lead us to belie-
ve that this patient was affected by IRIS and not a simple 
progression of the Kaposi sarcoma. 
The first is that there was no clinical progression of 
the Kaposi sarcoma lesions (neither in number nor in 
size) in the month before beginning HAART and the time 
elapsed between early use of HAART and the worsening 
of the patient’s lesions (about 6 weeks). According to 
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Fig 2 - New ulcerated lesions on chest.
Fig 3 - Normal and newly formed blood vessels in superficial 
dermis (H&E, 100x).
Fig 4 - Small vascular and slit-like spaces, lined by delicate 
endothelial cells; some spaces show evidence of red blood 
cells infiltration (H&E, 400x).
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the literature, the development of new lesions due to 
IRIS occur within 8 weeks (usually ranging from 3 to 
22 weeks) after initiating HAART8. During the immune 
status restoration the ability to mount an inflammatory 
response to a variety of previously indolent antigens is 
also restored10. This fact can result in clinical signs of di-
sease activity5, triggered by antigenic stimuli which can 
be tumor antigens or pathogens present in the body (but 
clinically latent), rather than development or progres-
sion of opportunistic infections11. 
In addiction, according to French et al12 our patient 
presents a major criteria: atypical presentation of tumor 
in patients responding to HAART with exaggerated in-
flammatory reaction (eg, severe fever or painful lesions) 
and 2 minor criteria: increased CD4 cell account and 
spontaneous resolution of disease without specific an-
timicrobial therapy or tumor chemotherapy with con-
tinuation of HAART. Our case is also consisted with 
Robertson J, et al case definition of IRIS13.
Most IRIS events are represented by the occurren-
ce or recurrence of dermatological diseases14. KS flare 
attributed to IRIS may produce life-threatening visceral 
progression even if cutaneous nodules regress, with 
deaths from pulmonary KS5,15. Visceral manifestations 
of the disease was not observed in our patient but the. 
cutaneous nodules enlargement can rapidly and fre-
quently ulcerate and lead to secondary infection16,17. 
In turn, the diagnosis of KS was confirmed by skin 
biopsy. The skin lesions of KS can be divided into patch, 
plaque and nodular stages, but these stages often over-
lap clinically and histologically18. In this report, the le-
sions exhibit features of nodular stage with a network 
of slit-like vascular spaces and erythrocytes within the 
narrow vascular clefts18,19.
In the medical literature revised till now, there are 
no specific guidelines for the diagnosis and treatment 
of IRIS12. However, the antiretroviral therapy should not 
be discontinued, except in the severely ill patients14,20. In 
our patient, this approach was successful showing the 
benefit of the continuation of HAART.
We can conclude that the clinician should be aware 
to identify signs and symptoms of neoplasm progression 
and to differentiate them from KS related IRIS and thus, 
to choose the better approach in the patient’s follow-up. 
REFERENCES
1. Goedert JJ. The epidemiology of acquired immuno-
deficiency syndrome malignancies. Semin Oncol. 
2000; 27(4): 390-401. 
2. Dourmishev LA, Dourmishev AL, Palmeri D, Sch-
wartz RA, Lukac DM. Molecular genetics of Kaposi’s 
sarcoma associated herpesvirus (human herpesvi-
rus-8) epidemiology and pathogenesis. Microbiol 
Mol Biol Rev. 2003; 67(2):175-212. 
3. Yoshioka MC, Alchorne MM, Porro AM, Tomimori-
-Yamashita J. Epidemiology of Kaposi’s sarcoma 
in patients with acquired immunodeficiency syn-
drome in Sao Paulo, Brazil. Int J Dermatol. 2004; 
43(9):643-7. 
4. Tamburro KM, Yang D, Poisson J, Fedoriw Y, Roy 
D, Lucas A, et al. Vironome of Kaposi sarcoma as-
sociated herpesvirus-inflammatory cytokine syn-
drome in an AIDS patient reveals co-infection of 
human herpesvirus 8 and human herpesvirus 6A. 
Virology. 2012; 433(1):220-5. 
5. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-
-Davis T, Mandalia S, et al. Immune reconstitution 
inflammatory syndrome associated with Kaposi’s 
sarcoma. J Clin Oncol. 2005; 23(22):5224-8. 
6. Murdoch DM, Venter WD, Feldman C, Van Rie A. 
Incidence and risk factors for the immune recons-
titution inflammatory syndrome in HIV patients 
in South Africa: a prospective study. AIDS. 2008; 
22(5):601-10. 
7. Nasti G, Martellotta F, Berretta M, Mena M, Fasan 
M, Di Perri G, et al. Impact of highly active antire-
troviral therapy on the presenting features and ou-
tcome of patients with acquired immunodeficiency 
syndrome-related Kaposi sarcoma. Cancer. 2003; 
98(11):2440-6. 
8. Feller L, Lemmer J. Insights into pathogenic events 
of HIV-associated Kaposi sarcoma and immune re-
constitution syndrome related Kaposi sarcoma. In-
fect Agent Cancer. 2008; 3:1. 
9. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Im-
mune reconstitution in HIV-infected patients. Clin 
Infect Dis. 2004; 38(8):1159-66. 
10. Lederman MM. Immune restoration and CD4+ T-
-cell function with antiretroviral therapies. AIDS. 
2001; 15 (Suppl 2):S11-5. 
11. Connick, E; Kane, MA; White, IE; Ryder, J; Cam-
pbell, TB. Immune Reconstitution Inflammatory 
Syndrome Associated with Kaposi Sarcoma during 
Potent Antiretroviral Therapy. Clin Infect Dis. 2004; 
39(12):1852-5. 
12. French MA, Price P, Stone SF. Immune restoration 
disease after antiretroviral therapy. AIDS. 2004; 
18(12):1615-27. 
13. Robertson J, Meier M, Wall J, Ying J, Fichten-
baum CJ. Immune reconstitution syndrome in HIV: 
Revista SPDV 71(2) 2013; Felipe Ladeira de Oliveira, Deborah Maria Brito Sírio, Gisele Cerutti,et cols; 
Sarcoma de Kaposi associado à Síndrome de Reconstituição Imune.
239
Caso Clínico
Revista SPDV 71(2) 2013; Felipe Ladeira de Oliveira, Deborah Maria Brito Sírio, Gisele Cerutti,et cols; 
Sarcoma de Kaposi associado à Síndrome de Reconstituição Imune.
validating a case definition and identifying clinical 
predictors in persons initiating antiretroviral thera-
py. Clin Infect Dis 2006; 42 (11):1639-46. 
14. Papagatsia Z, Jones J, Morgan P, Tappuni AR. Oral 
Kaposi sarcoma: a case of immune reconstitution 
inflammatory syndrome. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod. 2009; 108(1):70-5. 
15. Lehloenya R, Meintjes G. Dermatologic manifes-
tations of the immune reconstitution inflammatory 
syndrome. Dermatol Clin. 2006; 24(4):549-70, vii. 
16. Nguyen S, Giurca C, Melliez H, Dehecq C, Baclet 
V, Ajana F, et al. Kaposi’s sarcoma in HIV-infected 
patients: when and how should we evaluate bone 
involvement? AIDS. 2007; 21(16):2251-2. 
17. Von Roenn JH. Clinical presentations and standard 
therapy of AIDS-associated Kaposi’s sarcoma. 
Hematol Oncol Clin North Am. 2003; 17(3):747-
62. 
18. Calonje, E. Soft-Tissue Tumours and Tumour-like 
Conditions. In: Burns T,  Breathnach S, Cox N, Gri-
ffithsC, editors.  Rook's Textbook of Dermatology. 
8th ed.Oxford: Wiley-Blackwell; 2010. p. 56.35-
56.36
19. Buonaguro FM, Tomesello ML, Buonaguro L, Sa-
triano RA, Ruocco E, Castello G, et al . Kaposi's 
sarcoma: aetiopathogenesis, histology and clini-
cal features. J Eur Acad Dermatol Venereol. 2003; 
17(2):138-54. 
20. Loke WC, Spittle MF, Mitchell S, Kulasegaram R. 
Timing of highly active antiretroviral therapy and 
chemotherapy for Kaposi’s sarcoma in patients with 
HIV infection. Int J STD AIDS. 2006; 17(8):565-6. 
